Yeah!! Looking forward to working with you!

An Understudied Type of Breast Cancer Poses a Lurking Threat Matt Sikora, PhD, seeks better answers for lobular breast cancer, which can be harder to detect & has lower survival rates after several years than other types.

#LobularBreastCancerAwarenessDay: New research from CU Cancer Center member Matthew Sikora, PhD, seeks ways to potentially open up a new treatment option for people with this challenging cancer type ⬇️
https://news.cuanschutz.edu/cancer-center/sikora-lobular-breast-cancer

An Understudied Type of Breast Cancer Poses a Lurking Threat Matt Sikora, PhD, seeks better answers for lobular breast cancer, which can be harder to detect & has lower survival rates after several years than other types.

Amazing research being done to understand and cure ILC breast cancer!! news.cuanschutz.edu/cancer-cente... @mjsikora.bsky.social

🔬Don’t miss Session 2 of our gynecologic cancer virtual series! Scott Lin, MD, PhD Candidate, will share insights on PARP inhibitors & ovarian cancer treatment. #OvarianCancer @uccc-gorg.bsky.social

📅 Aug 11 |🕛 12–1PM MST |💻 Virtual
Topic: PARP Inhibitors
Register today! bit.ly/40k8dUE

Dr. Kian Behbakht and AOA Dx CEO Oriana Papin-Zoghbi spoke with 360Dx about the urgent need for better ovarian cancer diagnostics, highlighting how vague symptoms delay care and the role of innovation and data in closing this critical diagnostic gap. #OvarianCancer

👏Full article: bit.ly/3ZMxqa3

For Uterine Cancer Awareness Month, learn about the two primary types of uterine cancer and the symptoms to watch out for: bit.ly/45vieSg

Undermining Women’s Health Research — Gambling with the Public’s Health | NEJM The benefits of women’s health research haven’t been limited to women. But actions by the Trump administration threaten to dismantle the hard-won progress in this area.

Undermining Women’s Health Research — Gambling with the Public’s Health | New England Journal of Medicine www.nejm.org/doi/full/10....

Fight for Women’s Health! @cucancerbio.bsky.social

The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective

Insights on IHC testing for clinical decision making - put together by our talented Gyn Onc Path team! Shout to Dr. Rebecca Wolsky.

@cucancercenter.bsky.social

www.sciencedirect.com/science/arti...

New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab Four leading ovarian cancer research charities from four countries are funding a new AI Accelerator Grant in partnership with Microsoft’s AI for Good Lab to supercharge the next cancer research breakt...

New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab to Launch First-Of-Its-Kind $1M Global Grant to Improve Survival Rates ocrahope.org/news/new-glo...

🔬Curious about gynecologic cancer research but not a science expert? Join CU DRS & CGCA’s new virtual, quarterly series making cutting-edge research easy to understand @uccc-gorg.bsky.social

📅 May 12 |🕛 12–1PM MST |💻 Virtual
Topic: Ovarian cancer early detection
Register today! loom.ly/7owjJ-g

MSTP retreat - Scott presenting his research findings on targeting the epigenetic environment of therapy resistant ovarian cancer. @cucancercenter.bsky.social @cugynonc.bsky.social

Two people standing in front of a poster.

MSTP retreat - Raquel presenting her exciting research on Alt-EJ and PARP inhibitors. @cucancercenter.bsky.social @cugynonc.bsky.social

Feasibility of assessing symptoms associated with ovarian cancer using an electronic medical intake questionnaire Symptoms occur in up to 75% of patients with early-stage ovarian cancer; as such, using a symptom inventory (SI) to stratify which patients should rec…

Early detection for ovarian cancer. Drs. Helm and Behbakht published a study on symptom screening feasibility. www.sciencedirect.com/science/arti... @cucancercenter.bsky.social @cugynonc.bsky.social @powelldrescher.bsky.social @targetovarian.bsky.social

Last month, Taylor Benson, PhD, showcased her work on identifying early biomarkers for ovarian clear cell carcinoma (OCCC) at STEM Poster Day, hosted by @projbridgeco.bsky.social!
#CancerResearch #CUAnschutz

Check out her poster: www.cuanschutz.edu/docs/librari...

@cucancercenter.bsky.social

A sad few days for the NIH, a tragedy for sure. Sad days for science, education, innovation in the US and, truly, globally. Wow

Women-founded company partners with CU Anschutz to develop, test first-of-its-kind ovarian cancer detection test Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the cutting edge to detect and prevent ovarian cancer.

Early detection of ovarian cancer! www.cbsnews.com/colorado/new... @cugynonc.bsky.social @ocacademy.bsky.social

Dr. Davidson submitted a proposal to the Boettcher Foundation! Single-cell sequencing revealed that High-grade serous carcinoma subtypes are driven by microenvironment changes. She seeks to redefine HGSC subtypes & assess functional impacts on biomarkers w/ chemotherapy.🤞#HGSC #GynOnc #CUAnschutz

CDKN2ALow cancer cells outcompete macrophages for microenvironmental zinc to drive immunotherapy resistance Approximately 50% of cancers exhibit decreased CDKN2A expression ( CDKN2A Low), which is linked to immune checkpoint blockade (ICB) resistance. While CDKN2A is traditionally recognized as a tumor supp...

At the Keystone Tumor Metabolism meeting! Just listened to an incredible presentation by @airdlab.bsky.social highlighting the intersection of p16/metabolism/immunology! Check out the BiorXiv pre-print www.biorxiv.org/content/10.1...

Annika rightfully points out that though this is positive, this is going to SERIOUSLY burden an NIH staff that is actively being further depleted.

Be nice to your SROs, POs, and GMSs, folks...

CDMRP-funded cancer research was a strong commitment from the US that it cares about improving the outcomes for people with this terrible disease. The 57% cut to CDMRP highlights the total disrespect and lack of commitment from this administration to Americans with cancer.

There is SO MUCH RESEARCH that will simply NOT HAPPEN without these funds. We will be set back DECADES.

And for what? Greed. Hate. Spite.

I am crushed for the team at CDMRP that continues to support us, and for the work that will never be done.

Today the @cugynonc.bsky.social hosted Dr. Lea to honor Carol Goldstein! Carol was passionate about ovarian cancer early detection and symptom screening! Dr. Lea discussing hereditary ovarian risk. @tinaswish.bsky.social

8 years ago @asbmb.bsky.social gave me +18 more trainees a crash course in advocacy for their DC Hill Day. With NIH slashing indirect costs effective immediately, university Govt Affairs teams will be swamped. Here's 10 tips for scientists contacting lawmakers +pics from Denver's 2017 Science March.

Eager to hear my Rep, @degette.house.gov , and @bennet.senate.gov, respond to these seismic cuts. This isn't cost cutting or trimming fat, it's destroying the foundation of research and medical infrastructure in this country. Heartened to see @murray.senate.gov's response.

This is what amounts to an ILLEGAL & indiscriminate funding cut for research centers everywhere. It will mean shuttering labs across the country, layoffs in red & blue states, and derailing lifesaving research on everything from cancer to opioid addiction.

We all need to speak out to save lives.